Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Curcuminoids Modulated the IL-6/JAK/STAT3 Signaling Pathway in LoVo and HT-29 Colorectal Cancer Cells

Author(s): Qian Li, Yanting Ding, Ying Ou, Manjing Li, Ponsiree Jithavech, Visarut Buranasudja, Boonchoo Sritularak, Yichun Xu*, Pornchai Rojsitthisak* and Junsong Han*

Volume 29, Issue 36, 2023

Published on: 08 November, 2023

Page: [2867 - 2876] Pages: 10

DOI: 10.2174/0113816128263974231029180947

Price: $65

conference banner
Abstract

Background: Curcuminoids, including curcumin, desmethoxycurcumin, and bisdesmethoxycurcumin, are natural polyphenolic compounds that exhibit various biological properties, such as antioxidant, anti-inflammatory, and anticancer activities. Dysregulation of the interleukin (IL)-6-mediated Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway is closely associated with the development of colorectal cancer (CRC).

Methods: Here, we have evaluated the modulation of the IL-6/JAK/STAT3 pathway of curcumin, desmethoxycurcumin, and bisdesmethoxycurcumin in LoVo and HT-29 colorectal cancer cells with a single molecular array (Simoa), western blot analysis, real-time polymerase chain reaction (PCR), and pathway analysis system.

Results: The study showed that curcuminoids suppressed the amount of IL-6 in LoVo and HT-29 colorectal cancer cells. Meanwhile, curcuminoids inhibited the expression of inflammation regulator-related microRNA (miRNA). We also found that the expression of total STAT3 was downregulated by curcuminoids. Moreover, the pathway analysis system showed that curcuminoids inactivated the JAK/STAT3 signaling pathway. Taken together, we demonstrated that the anti-cancer activities of curcuminoids against colorectal cancer are due to the modulation of the IL-6/JAK/STAT3 cascade.

Conclusion: Curcuminoids could be a promising anti-cancer agent for the treatment of human colorectal cancer.

« Previous Next »
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 2019; 394(10207): 1467-80.
[http://dx.doi.org/10.1016/S0140-6736(19)32319-0] [PMID: 31631858]
[3]
Brown KGM, Solomon MJ, Mahon K, O’Shannassy S. Management of colorectal cancer. BMJ 2019; 366: l4561.
[http://dx.doi.org/10.1136/bmj.l4561] [PMID: 31439545]
[4]
Xu Y, Han S, Lei K, et al. Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells. Eur J Cancer Prev 2016; 25(6): 481-9.
[http://dx.doi.org/10.1097/CEJ.0000000000000205] [PMID: 26340059]
[5]
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144(5): 646-74.
[http://dx.doi.org/10.1016/j.cell.2011.02.013] [PMID: 21376230]
[6]
Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol 2021; 21(10): 653-67.
[http://dx.doi.org/10.1038/s41577-021-00534-x] [PMID: 33911231]
[7]
Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer 2015; 113(3): 365-71.
[http://dx.doi.org/10.1038/bjc.2015.233] [PMID: 26151455]
[8]
Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog 2013; 52(2): 155-66.
[http://dx.doi.org/10.1002/mc.21841] [PMID: 22121102]
[9]
Tang S, Yuan X, Song J, Chen Y, Tan X, Li Q. Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer. Oncol Lett 2019; 17(1): 159-64.
[PMID: 30655751]
[10]
Tomeh M, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019; 20(5): 1033.
[http://dx.doi.org/10.3390/ijms20051033] [PMID: 30818786]
[11]
Kim HY, Park EJ, Joe E, Jou I. Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J Immunol 2003; 171(11): 6072-9.
[http://dx.doi.org/10.4049/jimmunol.171.11.6072] [PMID: 14634121]
[12]
Zhao HM, Xu R, Huang XY, et al. Curcumin suppressed activation of dendritic cells via JAK/STAT/SOCS signal in mice with experimental colitis. Front Pharmacol 2016; 7: 455.
[http://dx.doi.org/10.3389/fphar.2016.00455] [PMID: 27932984]
[13]
Zhang X, Wu J, Ye B, Wang Q, Xie X, Shen H. Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway. BMC Complement Altern Med 2016; 16(1): 299.
[http://dx.doi.org/10.1186/s12906-016-1273-z] [PMID: 27544348]
[14]
Porro C, Cianciulli A, Trotta T, Lofrumento DD, Panaro MA. Curcumin regulates anti-inflammatory responses by JAK/STAT/ SOCS signaling pathway in BV-2 microglial cells. Biology (Basel) 2019; 8(3): 51.
[http://dx.doi.org/10.3390/biology8030051] [PMID: 31252572]
[15]
Wang Z, Jin H, Xu R, Mei Q, Fan D. Triptolide downregulates Rac1 and the JAK/STAT3 pathway and inhibits colitis-related colon cancer progression. Exp Mol Med 2009; 41(10): 717-27.
[http://dx.doi.org/10.3858/emm.2009.41.10.078] [PMID: 19561401]
[16]
Li J, Li X, Lan L, et al. ZNF32 promotes the self-renewal of colorectal cancer cells by regulating the LEPR-STAT3 signaling pathway. Cell Death Dis 2022; 13(2): 108.
[http://dx.doi.org/10.1038/s41419-022-04530-4] [PMID: 35115495]
[17]
Wichitnithad W, Nimmannit U, Wacharasindhu S, Rojsitthisak P. Synthesis, characterization and biological evaluation of succinate prodrugs of curcuminoids for colon cancer treatment. Molecules 2011; 16(2): 1888-900.
[http://dx.doi.org/10.3390/molecules16021888] [PMID: 21343891]
[18]
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol 2016; 37(9): 11553-72.
[http://dx.doi.org/10.1007/s13277-016-5098-7] [PMID: 27260630]
[19]
Patel SAA, Gooderham NJ. IL6 mediates immune and colorectal cancer cell cross-talk via miR-21 and miR-29b. Mol Cancer Res 2015; 13(11): 1502-8.
[http://dx.doi.org/10.1158/1541-7786.MCR-15-0147] [PMID: 26184038]
[20]
Jeffries J, Zhou W, Hsu AY, Deng Q. miRNA-223 at the crossroads of inflammation and cancer. Cancer Lett 2019; 451: 136-41.
[http://dx.doi.org/10.1016/j.canlet.2019.02.051] [PMID: 30878527]
[21]
Zhong L, Jin X, Xu Z, et al. Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma. Oncol Lett 2020; 20(5): 1.
[http://dx.doi.org/10.3892/ol.2020.12126] [PMID: 32989397]
[22]
Zanoaga O, Braicu C, Chiroi P, et al. The role of miR-155 in nutrition: Modulating cancer-associated inflammation. Nutrients 2021; 13(7): 2245.
[http://dx.doi.org/10.3390/nu13072245] [PMID: 34210046]
[23]
Garo LP, Ajay AK, Fujiwara M, et al. MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat Commun 2021; 12(1): 2419.
[http://dx.doi.org/10.1038/s41467-021-22641-y] [PMID: 33893298]
[24]
Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2018; 15(4): 234-48.
[http://dx.doi.org/10.1038/nrclinonc.2018.8] [PMID: 29405201]
[25]
Zuo C, Sheng X, Ma M, Xia M, Ouyang L. ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget 2016; 7(45): 74393-409.
[http://dx.doi.org/10.18632/oncotarget.11911] [PMID: 27626310]
[26]
Lin Q, Lai R, Chirieac LR, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: Inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167(4): 969-80.
[http://dx.doi.org/10.1016/S0002-9440(10)61187-X] [PMID: 16192633]
[27]
Du W, Hong J, Wang YC, et al. Inhibition of JAK2/STAT3 signalling induces colorectal cancer cell apoptosis via mitochondrial pathway. J Cell Mol Med 2012; 16(8): 1878-88.
[http://dx.doi.org/10.1111/j.1582-4934.2011.01483.x] [PMID: 22050790]
[28]
Corvinus FM, Orth C, Moriggl R, et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005; 7(6): 545-55.
[http://dx.doi.org/10.1593/neo.04571] [PMID: 16036105]
[29]
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009; 9(11): 798-809.
[http://dx.doi.org/10.1038/nrc2734] [PMID: 19851315]
[30]
Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: Short-term friend, long-term foe. Clin Cancer Res 2009; 15(2): 425-30.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-0149] [PMID: 19147746]
[31]
Wang SW, Sun YM. The IL-6/JAK/STAT3 pathway: Potential therapeutic strategies in treating colorectal cancer. Int J Oncol 2014; 44(4): 1032-40.
[http://dx.doi.org/10.3892/ijo.2014.2259] [PMID: 24430672]
[32]
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer 2021; 21(1): 22-36.
[http://dx.doi.org/10.1038/s41568-020-00306-0] [PMID: 33082563]
[33]
Fang G, Liu J, Wang Q, et al. MicroRNA-223-3p regulates ovarian cancer cell proliferation and invasion by targeting SOX11 expression. Int J Mol Sci 2017; 18(6): 1208.
[http://dx.doi.org/10.3390/ijms18061208] [PMID: 28587313]
[34]
Ji Q, Xu X, Song Q, et al. miR-223-3p inhibits human osteosarcoma metastasis and progression by directly targeting CDH6. Mol Ther 2018; 26(5): 1299-312.
[http://dx.doi.org/10.1016/j.ymthe.2018.03.009] [PMID: 29628305]
[35]
Chai B, Guo Y, Cui X, et al. MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. Am J Transl Res 2019; 11(7): 4516-23.
[PMID: 31396355]
[36]
Han HG, Moon HW, Jeon YJ. ISG15 in cancer: Beyond ubiquitin- like protein. Cancer Lett 2018; 438: 52-62.
[http://dx.doi.org/10.1016/j.canlet.2018.09.007] [PMID: 30213559]
[37]
Cheriyamundath S, Basu S, Haase G, et al. ISG15 induction is required during L1-mediated colon cancer progression and metastasis. Oncotarget 2019; 10(67): 7122-31.
[http://dx.doi.org/10.18632/oncotarget.27390] [PMID: 31903170]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy